GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kindred Biosciences Inc (NAS:KIN) » Definitions » Equity-to-Asset

Kindred Biosciences (Kindred Biosciences) Equity-to-Asset : 0.73 (As of Jun. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Kindred Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kindred Biosciences's Total Stockholders Equity for the quarter that ended in Jun. 2021 was $79.77 Mil. Kindred Biosciences's Total Assets for the quarter that ended in Jun. 2021 was $108.87 Mil. Therefore, Kindred Biosciences's Equity to Asset Ratio for the quarter that ended in Jun. 2021 was 0.73.

The historical rank and industry rank for Kindred Biosciences's Equity-to-Asset or its related term are showing as below:

KIN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.21   Med: 0.94   Max: 0.98
Current: 0.73

During the past 9 years, the highest Equity to Asset Ratio of Kindred Biosciences was 0.98. The lowest was -0.21. And the median was 0.94.

KIN's Equity-to-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.59 vs KIN: 0.73

Kindred Biosciences Equity-to-Asset Historical Data

The historical data trend for Kindred Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindred Biosciences Equity-to-Asset Chart

Kindred Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.94 0.93 0.86 0.72 0.70

Kindred Biosciences Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.73 0.70 0.76 0.73

Competitive Comparison of Kindred Biosciences's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Kindred Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindred Biosciences's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kindred Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Kindred Biosciences's Equity-to-Asset falls into.



Kindred Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Kindred Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Equity to Asset (A: Dec. 2020 )=Total Stockholders Equity/Total Assets
=67.482/95.814
=0.70

Kindred Biosciences's Equity to Asset Ratio for the quarter that ended in Jun. 2021 is calculated as

Equity to Asset (Q: Jun. 2021 )=Total Stockholders Equity/Total Assets
=79.769/108.872
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kindred Biosciences  (NAS:KIN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Kindred Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Kindred Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindred Biosciences (Kindred Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1555 Bayshore Highway, Suite 200, Burlingame, CA, USA, 94010
Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.
Executives
Richard Chin director, officer: Chief Executive Officer C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Denise Bevers director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Wendy Wee officer: Chief Financial Officer C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304
Hangjun Zhan officer: Chief Scientific Officer C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Joseph S Mccracken director C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Herbert D Montgomery director C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066
Raymond Townsend director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ervin Veszpremi director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Stephen Sundlof officer: SVP of Regulatory Affairs C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Oleg Nodelman director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Selby Blake Hawley officer: Chief Commercial Officer C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010
Stephen S Galliker officer: Chief Financial Officer 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Kevin Schultz officer: Chief Scientific Officer C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010

Kindred Biosciences (Kindred Biosciences) Headlines